<DOC>
	<DOCNO>NCT01429168</DOCNO>
	<brief_summary>This two-part study evaluate effectiveness etoricoxib control pain participant osteoarthritis experience inadequate response current treatment . In Part 1 , participant receive open-label etoricoxib 60 mg daily . Those participant experience clinically meaningful response etoricoxib 60 mg daily within two week eligible enter double-blind withdrawal period ( Part II ) . Responders enter Part 2 randomize 1:1 ratio receive either etoricoxib 60 mg placebo .</brief_summary>
	<brief_title>A Study Etoricoxib Participants With Osteoarthritis Not Responding Analgesic Drugs ( MK-0663-142 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Clinical diagnosis osteoarthritis knee hip require treatment American Rheumatism Association ( ARA ) functional Class I , II III Receiving stable dose traditional nonsteroidal antiinflammatory drug ( NSAID ) , Cox2 selective inhibitor ( etoricoxib , e.g . celecoxib ) , opioid therapy tramadol treat osteoarthritisrelated pain least 2 week willing maintain treatment baseline phase Moderate severe daily pain intensity current pain regimen Excepting osteoarthritis , patient judge otherwise general good health base medical history , physical examination , routine laboratory test Negative serum pregnancy test Has experience least 3 consecutive day daily pain intensity &gt; 4 10point scale Severe hepatic insufficiency Advanced renal insufficiency Presence gastrointestinal ulcer disease active bleeding history within past 6 month presence history inflammatory bowel disease History gastric , biliary ( include gastric bypass surgery ) , small intestinal surgery result clinical malabsorption Receiving likely require treatment â‰¥14 consecutive day repeat course pharmacologic dos corticosteroid Established ischemic heart disease , peripheral arterial disease , and/or cerebrovascular disease include history stroke , myocardial infarction transient ischemic attack , recent revascularization procedures Any contraindication mention approve study drug European Union ( EU ) Summary Product Characteristics ( SmPC ) Therapy glucosamine and/or chondroitin sulfate &lt; 6 month prior study start .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>